Cargando…
Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan(®) Medicaid Mult...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895443/ https://www.ncbi.nlm.nih.gov/pubmed/23229052 http://dx.doi.org/10.1007/s10597-012-9561-7 |
_version_ | 1782299967791038464 |
---|---|
author | Abouzaid, Safiya Tian, Haijun Zhou, Huanxue Kahler, Kristijan H. Harris, Michelle Kim, Edward |
author_facet | Abouzaid, Safiya Tian, Haijun Zhou, Huanxue Kahler, Kristijan H. Harris, Michelle Kim, Edward |
author_sort | Abouzaid, Safiya |
collection | PubMed |
description | No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan(®) Medicaid Multi-State Database (2004–2009) was conducted. Patients with schizophrenia and newly initiated on an AAP were included. Patients with and without extrapyramidal symptoms were matched using propensity-score matching. Healthcare utilization and costs were assessed in the 12-month follow-up period using logistic and two-part (gamma) regression models. Of 4,621 patients, 583 (12.6 %) had extrapyramidal symptoms. Patients with extrapyramidal symptoms had significantly more schizophrenia-related and all-cause hospitalizations and schizophrenia-related emergency room visits, as well as significantly higher schizophrenia-specific and all-cause total healthcare, inpatient, and prescription drug costs compared to patients without extrapyramidal symptoms. Extrapyramidal symptoms in patients with schizophrenia is associated with increased healthcare resource utilization and higher medical costs. |
format | Online Article Text |
id | pubmed-3895443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-38954432014-01-24 Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia Abouzaid, Safiya Tian, Haijun Zhou, Huanxue Kahler, Kristijan H. Harris, Michelle Kim, Edward Community Ment Health J Original Paper No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan(®) Medicaid Multi-State Database (2004–2009) was conducted. Patients with schizophrenia and newly initiated on an AAP were included. Patients with and without extrapyramidal symptoms were matched using propensity-score matching. Healthcare utilization and costs were assessed in the 12-month follow-up period using logistic and two-part (gamma) regression models. Of 4,621 patients, 583 (12.6 %) had extrapyramidal symptoms. Patients with extrapyramidal symptoms had significantly more schizophrenia-related and all-cause hospitalizations and schizophrenia-related emergency room visits, as well as significantly higher schizophrenia-specific and all-cause total healthcare, inpatient, and prescription drug costs compared to patients without extrapyramidal symptoms. Extrapyramidal symptoms in patients with schizophrenia is associated with increased healthcare resource utilization and higher medical costs. Springer US 2012-11-16 2014 /pmc/articles/PMC3895443/ /pubmed/23229052 http://dx.doi.org/10.1007/s10597-012-9561-7 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Paper Abouzaid, Safiya Tian, Haijun Zhou, Huanxue Kahler, Kristijan H. Harris, Michelle Kim, Edward Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia |
title | Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia |
title_full | Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia |
title_fullStr | Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia |
title_full_unstemmed | Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia |
title_short | Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia |
title_sort | economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895443/ https://www.ncbi.nlm.nih.gov/pubmed/23229052 http://dx.doi.org/10.1007/s10597-012-9561-7 |
work_keys_str_mv | AT abouzaidsafiya economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia AT tianhaijun economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia AT zhouhuanxue economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia AT kahlerkristijanh economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia AT harrismichelle economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia AT kimedward economicburdenassociatedwithextrapyramidalsymptomsinamedicaidpopulationwithschizophrenia |